NCT04015232
Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
Phase: Phase 1
Role: Collaborator
Start: Feb 26, 2018
Completion: Jun 5, 2018